Can A New Cholesterol Drug Restore Merck ’s Prominence In Heart Drugs?

But, if successful, this drug has the potential to indeed become the PCSK9 inhibitor for the masses. It could bring Merck full circle back to the days of Mevacor and Zocor.

Source: Forbes.com Healthcare News - February 1, 2022 Category: Pharmaceuticals Authors: John LaMattina, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma Source Type: news